Genentech halted a clinical study yesterday after ovarian cancer patients suffered serious side effects. After the announcement, Genentech's...
Genentech halted a clinical study yesterday after ovarian cancer patients suffered serious side effects.
After the announcement, Genentech’s shares fell. Avastin, approved for the treatment for colon cancer, was considered Genentech’s most promising drug.
Genentech said it stopped accepting participants in the ovarian cancer study after five of 44 patients suffered bowel tears.
The clinical trial was testing Avastin for ovarian cancer patients whose disease did not respond to chemotherapy drugs containing platinum.
Most Read Stories
- This season, Seahawks have crossed the line from brash to just plain unlikable | Matt Calkins
- Seahawks coach Pete Carroll says Richard Sherman played second half of season with 'significant' knee injury
- Michael Bennett explodes at reporter following Seahawks-Falcons game
- Can’t make it to D.C.? Seattle will have own women’s march
- Patty Murray, Maria Cantwell criticized for vote to block prescription drugs from Canada
Jim Reddich, an analyst with Friedman, Billings, Ramsey, said that Avastin might not reach its peak sales potential of $7 billion if doctors became worried about safety. The drug is expected to have sales of $1 billion this year.
Shares of Genentech fell $2.17 to $85.83.